RxDoctor Payments Data

Charlisa Heyward

Nurse Practitioner · Hesperia, CANPI 1588218663

Payments from drug & device makers

$2,238in general payments, 2019–2025

Across 114 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$723
  • AbbVie$641
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$456
  • Scilex Pharmaceuticals Inc.$132
  • Valinor Pharma, LLC$90
  • Pfizer$37
  • plus $159 from 6 others

What the payments were for

  • Food & beverage$2,238100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,238 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$63,285
Medicare patients
121
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide35$74,421
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,675$36,414
ZtlidoLidocaine56$35,638
MovantikNaloxegol Oxalate86$33,780
Lidocaine224$22,492
BelbucaBuprenorphine Hcl25$20,487
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen664$17,768
OxycontinOxycodone Hcl39$16,329
Nurtec OdtRimegepant Sulfate11$11,658
Diclofenac Sodium242$9,243
Buprenorphine32$7,791
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl18$5,926
Gabapentin560$4,893
Xtampza ErOxycodone Myristate11$4,495
Pregabalin170$3,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$456$74,42135 claims
Scilex Pharmaceuticals Inc.Ztlido$132$35,63856 claims
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$18$24,98136 claims
PfizerNurtec Odt$37$11,65811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Hesperia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →